A Study of Low and Standard-dose Ticagrelor After Intervention for ACS Patients

• Status: Recruiting
• Trial end date: 2022-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is to evaluate the safety and efficacy of 60mg ticagrelor plus 100mg Aspirin to prevent major adverse cardiovascular and cerebrovascular events in one years after drug-eluting stents implantation for Chinese ACS patients compared with 90mg ticagrelor plus 100mg Aspirin

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai Tong Ren Hospital
• Collaborators: Fudan University; Shanghai Jiao Tong University School of Medicine
• Treatments: Aspirin; Ticagrelor

Criteria

Inclusion Criteria:

1. Subject must be at least 18 years of age

2. Patients should have undergone successful percutaneous coronary intervention with drug-eluting stent for acute coronary syndrome

3. Subject understand the study requirements and the treatment procedures and provided informed consent before the procedure

Exclusion Criteria:

1. Female of childbearing potential, unless a recent pregnancy test is negative, who possibly plan to become pregnant any time after enrollment into this study

2. Active bleeding

3. Known hypersensitivity or contraindication to study medications

4. Non-cardiac co-morbid conditions are present with life expectancy <2 year or that may result in protocol non-compliance (per site investigator's medical judgment).

5. Subjects with Cerebral hemorrhage history

6. Subjects with stroke history in half a year

7. subjects with malignant tumor

8. subjects with whom oral anticoagulants are needed